Thermo Fisher Scientific (TMO) Other financing activities (2009 - 2026)

Thermo Fisher Scientific (TMO) has reported Other financing activities for 18 consecutive years, with -$6.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other financing activities rose 85.71% year-over-year to -$6.0 million; the trailing twelve-month figure through Jun 2026 stood at $120.0 million (up 126.42% YoY), and the FY2025 full-year result was $90.0 million, down 53.85% from the prior year.
• Other financing activities fell to -$6.0 million in Q2 2026 per TMO's latest filing, from $39.0 million in the prior quarter.
• Across five years, Other financing activities topped out at $110.0 million in Q1 2024 and bottomed at -$42.0 million in Q2 2025.
• Historically, Other financing activities has averaged $20.3 million across 5 years, with a median of $19.0 million in 2022.
• The sharpest annual moves came in 2022 and 2024: Other financing activities sank 270.0% in 2022, then surged 775.0% in 2024.
• Over 5 years, Other financing activities stood at $20.0 million in 2022, then decreased by 30.0% to $14.0 million in 2023, then sank by 221.43% to -$17.0 million in 2024, then jumped by 635.29% to $91.0 million in 2025, then plunged by 106.59% to -$6.0 million in 2026.
• According to Business Quant data, Other financing activities over the past three periods registered -$6.0 million, $39.0 million, and $91.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.